LGI2 (Leucine-Rich Glioma Inactivated 2) is a secreted neuronal protein that belongs to the LGI family of leucine-rich repeat (LRR) domain-containing proteins. Alongside LGI1, LGI3, and LGI4, LGI2 plays critical roles in synaptic function, neuronal development, and increasingly recognized roles in neurodegeneration. The gene is located at chromosome 4p15.2, encodes a 509-amino acid secreted protein, and is expressed predominantly in the brain with particularly high levels in the cerebral cortex and hippocampus. While initially studied in the context of epilepsy and glioma, emerging evidence links LGI2 dysfunction to Alzheimer's disease, autism spectrum disorders, and other neurological conditions [Citation 1].
The LGI family proteins are characterized by their unique architecture: an N-terminal leucine-rich repeat (LRR) domain followed by three_epidermal growth factor (EGF)-like domains and a C-terminal leucine-rich repeat (LRRCT) domain. This structure enables LGI proteins to function as soluble ligands for ADAM (A Disintegrin and Metalloproteinase) family receptors, particularly ADAM22 and ADAM23, which are enriched at postsynaptic densities [Citation 2].
The LGI2 gene spans approximately 6.8 kb on chromosome 4p15.2 and consists of 10 exons encoding a 509-amino acid secreted protein. The gene structure shares significant homology with other LGI family members, particularly in the exon arrangement encoding the LRR and EGF domains [Citation 3].
LGI2 contains five distinct domains:
The protein contains an N-terminal signal peptide (residues 1-22) directing secretion via the secretory pathway.
The overall structure resembles a "V" shape, with the LRR domains forming one arm and the EGF/LRRCT domains forming the other, creating a ligand-binding cleft for ADAM receptors [Citation 4].
LGI2 primarily binds two ADAM family receptors:
ADAM22: Predominantly expressed in the brain, particularly in the hippocampus and cerebral cortex. ADAM22 localizes to postsynaptic densities of excitatory synapses, where it regulates AMPA receptor trafficking and synaptic strength [Citation 5].
ADAM23: Expressed primarily in the brain, with high levels in the cerebellum and brainstem. ADAM23 is localized to presynaptic terminals, where it may function in axonal guidance and presynaptic organization [Citation 6].
LGI2-ADAM22/23 signaling regulates:
Synaptic transmission: LGI2 modulates both excitatory and inhibitory synaptic transmission through ADAM22-mediated signaling.
AMPA receptor trafficking: ADAM22 interacts with GRIP1 and GRIP2 to regulate AMPA receptor scaffolding and trafficking [Citation 7].
Synaptic plasticity: LGI2 signaling contributes to long-term potentiation (LTP) and long-term depression (LTD).
Dendritic spine morphology: LGI2-ADAM22 regulates spine formation and maintenance.
Inhibitory synapses: Emerging evidence suggests LGI2 also modulates GABAergic synaptic function [Citation 8].
LGI2-ADAM22 engagement activates several intracellular signaling cascades:
LGI2 is expressed in:
Within the brain, LGI2 exhibits region-specific expression:
LGI2 is primarily localized to the somatodendritic compartment of neurons, consistent with its role as a postsynaptic ligand.
| Protein | Brain Expression | Primary Receptors | Key Functions |
|---|---|---|---|
| LGI1 | Highest in cortex, hippocampus | ADAM22, ADAM23 | Major synaptic regulator |
| LGI2 | Moderate, region-specific | ADAM22, ADAM23 | Redundant/modulatory |
| LGI3 | Broad | ADAM22, ADAM23 | Secreted, immune roles |
| LGI4 | Limited (oligodendrocytes) | ADAM22 | Myelination |
While LGI1 is the predominant functional LGI in most brain regions, LGI2 provides important redundant and modulatory functions, particularly in specific contexts [Citation 9].
LGI2 is increasingly implicated in Alzheimer's disease:
Expression alterations: LGI2 expression is significantly reduced in AD brain, particularly in early disease stages. Studies show decreased LGI2 in hippocampal tissue from AD patients [Citation 10].
Amyloid-β interactions: LGI2 levels correlate inversely with amyloid burden in AD brain. In vitro, Aβ treatment reduces LGI2 expression in neurons.
Synaptic dysfunction: As a synaptic organizer, LGI2 loss may contribute to synaptic failure in AD. ADAM22 levels are also altered in AD.
Genetic associations: Polymorphisms in the LGI2 gene have been associated with increased AD risk in some populations [Citation 11].
Therapeutic potential: LGI2-based therapies may help restore synaptic function in AD.
Autosomal Dominant Lateral Temporal Epilepsy (ADLTE): LGI2 mutations were initially identified as less penetrant modifiers of ADLTE. While LGI1 mutations are the primary cause, LGI2 variants may modulate disease severity [Citation 12].
LGI2 knockout mice: Show increased seizure susceptibility, supporting a protective role for LGI2.
Mechanism: LGI2-ADAM22 signaling regulates inhibitory synaptic function. Loss of LGI2 may lead to hyperexcitability.
Glioma: LGI2 functions as a tumor suppressor in certain glioma subtypes. Loss of LGI2 expression correlates with tumor grade.
Other tumors: LGI2 downregulated in various cancers including colorectal, breast, and renal cell carcinoma.
LGI2 contributes to synaptic function through multiple mechanisms:
Postsynaptic organization: LGI2-ADAM22 complexes organize the postsynaptic density, scaffolding AMPA receptors and associated proteins.
Receptor trafficking: ADAM22 interactions with GRIP1/GRIP2 regulate AMPA receptor cycling.
Plasticity regulation: LGI2 signaling modulates LTP and LTD through AMPA receptor modulation.
In neurodegeneration, LGI2 dysfunction contributes to synaptic failure through these mechanisms.
LGI2 plays roles in:
Neuronal migration: LGI2-ADAM23 signaling influences neuronal positioning during development.
Axonal guidance: Presynaptic ADAM23 may regulate axon pathfinding.
Synaptogenesis: LGI2 coordinates pre- and postsynaptic assembly during development [Citation 14].
Emerging evidence suggests LGI2 functions in:
Astrocyte-neuron communication: LGI2 secreted by astrocytes may signal to neurons.
Oligodendrocyte function: LGI2 expressed in oligodendrocytes, potential roles in myelination.
Microglial modulation: LGI2 may affect microglial function in neuroinflammation.
LGI2 is a secreted neuronal protein that plays important roles in synaptic function, neuronal development, and increasingly recognized roles in neurodegeneration. As a ligand for ADAM22 and ADAM23 receptors, LGI2 regulates synaptic transmission, AMPA receptor trafficking, and spine morphology. In Alzheimer's disease, LGI2 expression is reduced, contributing to synaptic dysfunction. While LGI1 is the predominant functional LGI in most brain regions, LGI2 provides important redundant and modulatory functions. Understanding LGI2's role in neurodegeneration may reveal therapeutic targets for synaptic protection.